Director Transaction

Hikma Pharmaceuticals Plc
31 May 2006




                   Notification of Transaction by a Director

LONDON, 31 May 2006 - Hikma Pharmaceuticals PLC (the 'Company') (LSE: HIK)
(DIFX:HIK) announces that Mr. Samih Darwazah, Chairman and Chief Executive of
the Company, has today notified the Company of the transfer of his entire direct
holding of 1,074,506 ordinary shares of 10 pence each in the capital of the
Company, to HMS Holding SAL, a company 99.66 percent owned by him. The remaining
outstanding shares of HMS Holding SAL are held equally between Mr. Darwazah's
wife, and his son, Mazen Darwazah. The transfer was made for nil consideration
and was made on 31 May 2006.

The shares transferred represent 0.642 per cent. of the issued ordinary shares
of 10 pence each in the capital of the Company, and following the notification
Mr. Darwazah no longer has a direct holding in the Company's ordinary shares.
HMS Holding SAL has agreed to continue the same lock-up arrangements as Mr.
Darwazah in respect of the shares transferred. The holding of Darhold Limited, a
company in which Mr. Darwazah is a shareholder, remains unchanged.

Mr. Darwazah is both a director and a Person Discharging Managerial
Responsibility in respect of the Company, and the above notification relates
both to DR 3.1.4R(1)(a) and section 324 (as extended by section 328) of the
Companies Act 1985.

                                   -- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC

Henry Knowles                                                 [phone]
Company Secretary
Susan Ringdal                                                 [phone]
Investor Relations Director

Brunswick Group

Jon Coles / Wendel Verbeek / Justine McIlroy / Alex Tweed    [phone]

About Hikma
Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ('MENA') region and Europe. In 2005, the Group
had revenue of $262 million and profit attributable to shareholders of $44
million. At 31 December 2005, the Group had over 1,800 employees. For news and
other information, please visit www.hikma.com.



                      This information is provided by RNS
            The company news service from the London Stock Exchange